PMID- 17823119 OWN - NLM STAT- MEDLINE DCOM- 20071213 LR - 20220129 IS - 0021-9258 (Print) IS - 0021-9258 (Linking) VI - 282 IP - 44 DP - 2007 Nov 2 TI - A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 is sumoylated and targeted to promyelocytic leukemia nuclear bodies in mutant SOD1-linked amyotrophic lateral sclerosis. PG - 32480-90 AB - EAAT2 (excitatory amino acid transporter 2) is a high affinity, Na+-dependent glutamate transporter of glial origin that is essential for the clearance of synaptically released glutamate and prevention of excitotoxicity. During the course of human amyotrophic lateral sclerosis (ALS) and in a transgenic mutant SOD1 mouse model of the disease, expression and activity of EAAT2 is remarkably reduced. We previously showed that some of the mutant SOD1 proteins exposed to oxidative stress inhibit EAAT2 by triggering caspase-3 cleavage of EAAT2 at a single defined locus. This gives rise to two fragments that we termed truncated EAAT2 and COOH terminus of EAAT2 (CTE). In this study, we report that analysis of spinal cord homogenates prepared from mutant G93A-SOD1 mice reveals CTE to be of a higher molecular weight than expected because it is conjugated with SUMO-1. The sumoylated CTE fragment (CTE-SUMO-1) accumulates in the spinal cord of these mice as early as presymptomatic stage (70 days of age) and not in other central nervous system areas unaffected by the disease. The presence and accumulation of CTE-SUMO-1 is specific to ALS mice, since it does not occur in the R6/2 mouse model for Huntington disease. Furthermore, using an astroglial cell line, primary culture of astrocytes, and tissue samples from G93A-SOD1 mice, we show that CTE-SUMO-1 is targeted to promyelocytic leukemia nuclear bodies. Since one of the proposed functions of promyelocytic leukemia nuclear bodies is regulation of gene transcription, we suggest a possible novel mechanism by which the glial glutamate transporter EAAT2 could contribute to the pathology of ALS. FAU - Gibb, Stuart L AU - Gibb SL AD - Farber Institute for Neurosciences, Weinberg Unit for ALS Research, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, and Cecil B. Day Laboratory for Neuromuscular Research, Massachusetts General Hospital, Charlestown 02129, USA. FAU - Boston-Howes, William AU - Boston-Howes W FAU - Lavina, Zeno S AU - Lavina ZS FAU - Gustincich, Stefano AU - Gustincich S FAU - Brown, Robert H Jr AU - Brown RH Jr FAU - Pasinelli, Piera AU - Pasinelli P FAU - Trotti, Davide AU - Trotti D LA - eng GR - GGP06268/TI_/Telethon/Italy GR - R01-NS44292/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20070906 PL - United States TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Excitatory Amino Acid Transporter 2) RN - 0 (SOD1 protein, human) RN - 0 (SUMO-1 Protein) RN - EC 1.15.1.1 (Sod1 protein, mouse) RN - EC 1.15.1.1 (Sod1 protein, rat) RN - EC 1.15.1.1 (Superoxide Dismutase) RN - EC 1.15.1.1 (Superoxide Dismutase-1) RN - EC 3.4.22.- (Caspase 3) SB - IM MH - Amyotrophic Lateral Sclerosis/*pathology MH - Animals MH - Animals, Genetically Modified MH - Astrocytes/metabolism MH - Caspase 3/*metabolism MH - Cell Nucleus Structures/metabolism MH - Excitatory Amino Acid Transporter 2/chemistry/*metabolism MH - Humans MH - Huntington Disease/pathology MH - Immunoprecipitation MH - Intranuclear Inclusion Bodies/*metabolism MH - Mice MH - Mice, Transgenic MH - Molecular Weight MH - Protein Structure, Tertiary MH - Rats MH - SUMO-1 Protein/*metabolism MH - Spinal Cord/pathology MH - Superoxide Dismutase/genetics/*metabolism MH - Superoxide Dismutase-1 EDAT- 2007/09/08 09:00 MHDA- 2007/12/14 09:00 CRDT- 2007/09/08 09:00 PHST- 2007/09/08 09:00 [pubmed] PHST- 2007/12/14 09:00 [medline] PHST- 2007/09/08 09:00 [entrez] AID - S0021-9258(20)43074-1 [pii] AID - 10.1074/jbc.M704314200 [doi] PST - ppublish SO - J Biol Chem. 2007 Nov 2;282(44):32480-90. doi: 10.1074/jbc.M704314200. Epub 2007 Sep 6.